Category Archives: J Invest Dermatol

Topical Gentamicin for the Treatment of Genetic Skin Diseases.

Posted on March 28, 2018 by

Related Articles
Topical Gentamicin for the Treatment of Genetic Skin Diseases.
J Invest Dermatol. 2018 Apr;138(4):731-734
Authors: Pasmooij AMG
Abstract
Clinical application of topical gentamicin is a… Continue reading →

Posted in J Invest Dermatol | Tagged , | Comments Off on Topical Gentamicin for the Treatment of Genetic Skin Diseases.

Epiplakin is a Paraneoplastic Pemphigus Autoantigen and Related to Bronchiolitis Obliterans in Japanese Patients.

Posted on October 21, 2015 by admin

Related Articles

Epiplakin is a Paraneoplastic Pemphigus Autoantigen and Related to Bronchiolitis Obliterans in Japanese Patients.

J Invest Dermatol. 2015 Oct 19;
…

Continue reading →

Posted in J Invest Dermatol | Tagged | Comments Off on Epiplakin is a Paraneoplastic Pemphigus Autoantigen and Related to Bronchiolitis Obliterans in Japanese Patients.

Large-Scale Electron Microscopy Maps of Patient Skin and Mucosa Provide Insight into Pathogenesis of Blistering Diseases.

Posted on March 20, 2015 by Sokol E, Kramer D, Diercks GF, Kuipers J, Jonkman MF, Pas HH, Giepmans BN

Large-Scale Electron Microscopy Maps of Patient Skin and Mucosa Provide Insight into Pathogenesis of Blistering Diseases.
J Invest Dermatol. 2015 Mar 19;
Authors: Sokol E, Kramer D, Diercks GF, Kuipers J, Jonkman MF,… Continue reading →

Posted in J Invest Dermatol | Comments Off on Large-Scale Electron Microscopy Maps of Patient Skin and Mucosa Provide Insight into Pathogenesis of Blistering Diseases.

Autoantibodies to Multiple Epitopes on the Non-Collagenous-1 Domain of Type VII Collagen Induce Blisters.

Posted on February 18, 2015 by Vorobyev A, Ujiie H, Recke A, Buijsrogge JJ, Jonkman MF, Pas HH, Iwata H, Hashimoto T, Kim SC, Hoon Kim J, Groves R, Samavedam U, Gupta Y, Schmidt E, Zillikens D, Shimizu H, Ludwig RJ

Autoantibodies to Multiple Epitopes on the Non-Collagenous-1 Domain of Type VII Collagen Induce Blisters.
J Invest Dermatol. 2015 Feb 17;
Authors: Vorobyev A, Ujiie H, Recke A, Buijsrogge JJ, Jonkman MF, Pas HH, Iwat… Continue reading →

Posted in J Invest Dermatol | Comments Off on Autoantibodies to Multiple Epitopes on the Non-Collagenous-1 Domain of Type VII Collagen Induce Blisters.

Transgenic mouse technology in skin biology: generation of knockin mice.

Posted on November 11, 2014 by Tellkamp F, Benhadou F, Bremer J, Gnarra M, Knüver J, Schaffenrath S, Vorhagen S

Transgenic mouse technology in skin biology: generation of knockin mice.

J Invest Dermatol. 2014 Dec;134(12):e27

Authors: Tellkamp F, Benhadou F, Bremer J, Gnarra M, Knüver J, Schaffenrath S, Vorhagen S

PMID: 25381772 [PubMed – in process]

Continue reading →

Posted in J Invest Dermatol | Comments Off on Transgenic mouse technology in skin biology: generation of knockin mice.

No evidence of apoptotic cells in pemphigus acantholysis.

Posted on August 21, 2014 by Janse IC, van der Wier G, Jonkman MF, Pas HH, Diercks GF

Related Articles

No evidence of apoptotic cells in pemphigus acantholysis.

J Invest Dermatol. 2014 Jul;134(7):2039-41

Authors: Janse IC, van der Wier G, Jonkman…

Continue reading →

Posted in J Invest Dermatol | Tagged | Comments Off on No evidence of apoptotic cells in pemphigus acantholysis.

From epidemiology and genetics to diagnostics, outcome measures, and novel treatments in autoimmune bullous diseases.

Posted on August 16, 2014 by Ludwig RJ, Borradori L, Diaz LA, Hashimoto T, Hertl M, Ibrahim SM, Jonkman MF, Kitajima Y, Murrell DF, Schmidt E, Shimizu H, Stanley JR, Woodley DT, Zillikens D

Related Articles
From epidemiology and genetics to diagnostics, outcome measures, and novel treatments in autoimmune bullous diseases.
J Invest Dermatol. 2014 Sep;134(9):2298-300
Authors: Ludwig RJ, Borradori L, Diaz … Continue reading →

Posted in J Invest Dermatol | Tagged , | Comments Off on From epidemiology and genetics to diagnostics, outcome measures, and novel treatments in autoimmune bullous diseases.

Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production.

Posted on May 29, 2014 by He X, Koenen HJ, Smeets RL, Keijsers R, van Rijssen E, Koerber A, van de Kerkhof PC, Boots AM, Joosten I

Related Articles

Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production.

J Invest Dermatol. 2014…

Continue reading →

Posted in J Invest Dermatol | Tagged | Comments Off on Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production.

Long-term survival of type XVII collagen revertant cells in an animal model of revertant cell therapy.

Posted on March 26, 2014 by Gostyński A, Llames S, García M, Escamez MJ, Martinez-Santamaria L, Nijenhuis M, Meana A, Pas HH, Larcher F, Pasmooij AM, Jonkman MF, Del Rio M

Related Articles

Long-term survival of type XVII collagen revertant cells in an animal model of revertant cell therapy.

J Invest Dermatol. 2014 Feb;134(2):571-4

Authors: …

Continue reading →

Posted in J Invest Dermatol | Tagged | Comments Off on Long-term survival of type XVII collagen revertant cells in an animal model of revertant cell therapy.

Smaller Desmosomes are Seen in the Skin of Pemphigus Patients with Anti-Desmoglein 1 Antibodies but not in Patients with Anti-Desmoglein 3 Antibodies.

Posted on March 14, 2014 by van der Wier G, Pas HH, Kramer D, Diercks GF, Jonkman MF

Smaller Desmosomes are Seen in the Skin of Pemphigus Patients with Anti-Desmoglein 1 Antibodies but not in Patients with Anti-Desmoglein 3 Antibodies.

J Invest Dermatol. 2014 Mar 12;
…

Continue reading →

Posted in J Invest Dermatol | Tagged | Comments Off on Smaller Desmosomes are Seen in the Skin of Pemphigus Patients with Anti-Desmoglein 1 Antibodies but not in Patients with Anti-Desmoglein 3 Antibodies.

Plectin mutations underlie epidermolysis bullosa simplex in 8% of patients.

Posted on March 6, 2014 by Bolling MC, Jongbloed JD, Boven LG, Diercks GF, Smith FJ, McLean WH, Jonkman MF

Related Articles
Plectin mutations underlie epidermolysis bullosa simplex in 8% of patients.
J Invest Dermatol. 2014 Jan;134(1):273-6
Authors: Bolling MC, Jongbloed JD, Boven LG, Diercks GF, Smith FJ, McLean WH, Jonkman MF
… Continue reading →

Posted in J Invest Dermatol | Tagged , | Comments Off on Plectin mutations underlie epidermolysis bullosa simplex in 8% of patients.

Mechanisms of Natural Gene Therapy in Dystrophic Epidermolysis Bullosa.

Posted on March 2, 2014 by Kiritsi D, Garcia M, Brander R, Has C, Meijer R, Jose Escámez M, Kohlhase J, van den Akker PC, Scheffer H, Jonkman MF, Del Rio M, Bruckner-Tuderman L, Pasmooij AM

Related Articles

Mechanisms of Natural Gene Therapy in Dystrophic Epidermolysis Bullosa.

J Invest Dermatol. 2014 Feb 27;

Authors: Kiritsi D, Garcia M, Brander R, Has C,…

Continue reading →

Posted in J Invest Dermatol | Tagged | Comments Off on Mechanisms of Natural Gene Therapy in Dystrophic Epidermolysis Bullosa.

High Anti-Staphylococcal Antibody Titers in Patients with Epidermolysis Bullosa Relate to Long-Term Colonization with Alternating Types of Staphylococcus aureus.

Posted on September 28, 2012 by van der Kooi-Pol MM, de Vogel CP, Westerhout-Pluister GN, Veenstra-Kyuchukova YK, Duipmans JC, Glasner C, Buist G, Elsinga GS, Westra H, Bonarius HP, Groen H, van Wamel WJ, Grundmann H, Jonkman MF, van Dijl JM

High Anti-Staphylococcal Antibody Titers in Patients with Epidermolysis Bullosa Relate to Long-Term Colonization with Alternating Types of Staphylococcus aureus.

J Invest Dermatol. 2012 Sep…

Continue reading →

Posted in J Invest Dermatol | Tagged , | Comments Off on High Anti-Staphylococcal Antibody Titers in Patients with Epidermolysis Bullosa Relate to Long-Term Colonization with Alternating Types of Staphylococcus aureus.

Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations.

Posted on June 19, 2012 by Pasmooij AM, Nijenhuis M, Brander R, Jonkman MF

Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations.

J Invest Dermatol. 2012 May;132(5):1374-83
…

Continue reading →

Posted in J Invest Dermatol | Tagged , | Comments Off on Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations.

The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells.

Posted on May 13, 2012 by Wiersma VR, de Bruyn M, van Ginkel RJ, Sigar E, Hirashima M, Niki T, Nishi N, Samplonius DF, Helfrich W, Bremer E

The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells.
J Invest Dermatol. 2012 May 10;
Authors: Wiersma VR, de Bruyn M, van Ginkel RJ, Sigar E, Hirashima M, Niki T, Nishi N, Samplonius DF, H… Continue reading →

Posted in J Invest Dermatol | Tagged , | Comments Off on The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells.

Realm of revertant mosaicism expanding.

Posted on February 14, 2012 by Jonkman MF, Pasmooij AM

Realm of revertant mosaicism expanding.

J Invest Dermatol. 2012 Mar;132(3):514-6

Authors: Jonkman MF, Pasmooij AM

Abstract

In this issue, Lai-Cheong et al. report…

Continue reading →

Posted in J Invest Dermatol | Tagged , | Comments Off on Realm of revertant mosaicism expanding.

Propionibacterium acnes activates the IGF-1/IGF-1R system in the epidermis and induces keratinocyte proliferation.

Posted on September 22, 2011 by Isard O, Knol AC, Ariès MF, Nguyen JM, Khammari A, Castex-Rizzi N, Dréno B

Propionibacterium acnes activates the IGF-1/IGF-1R system in the epidermis and induces keratinocyte proliferation.
J Invest Dermatol. 2011 Jan;131(1):59-66
Authors: Isard O, Knol AC, Ariès MF, Nguyen JM, Khammari A, Castex-Ri… Continue reading →

Posted in J Invest Dermatol | Tagged , | Comments Off on Propionibacterium acnes activates the IGF-1/IGF-1R system in the epidermis and induces keratinocyte proliferation.

Revertant mosaicism due to a second-site mutation in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa.

Posted on September 16, 2011 by Pasmooij AM, Garcia M, Escamez MJ, Nijenhuis AM, Azon A, Cuadrado-Corrales N, Jonkman MF, Del Rio M

Revertant mosaicism due to a second-site mutation in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa.
J Invest Dermatol. 2010 Oct;130(10):2407-11
Authors: Pasmooij AM, Garcia M, Escamez MJ, Nijenhuis AM, … Continue reading →

Posted in J Invest Dermatol | Tagged , | Comments Off on Revertant mosaicism due to a second-site mutation in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa.

Insights from a desmoplakin mutation identified in lethal acantholytic epidermolysis bullosa.

Posted on September 16, 2011 by Hobbs RP, Han SY, van der Zwaag PA, Bolling MC, Jongbloed JD, Jonkman MF, Getsios S, Paller AS, Green KJ

Insights from a desmoplakin mutation identified in lethal acantholytic epidermolysis bullosa.
J Invest Dermatol. 2010 Nov;130(11):2680-3
Authors: Hobbs RP, Han SY, van der Zwaag PA, Bolling MC, Jongbloed JD, Jonkman MF, Get… Continue reading →

Posted in J Invest Dermatol | Tagged , | Comments Off on Insights from a desmoplakin mutation identified in lethal acantholytic epidermolysis bullosa.

Keratin 14-null cells as a model to test the efficacy of gene therapy approaches in epithelial cells.

Posted on September 16, 2011 by D'Alessandro M, Coats SE, Jonkman MF, Jonkmann MF, Leigh IM, Lane EB

Keratin 14-null cells as a model to test the efficacy of gene therapy approaches in epithelial cells.
J Invest Dermatol. 2011 Jul;131(7):1412-9
Authors: D’Alessandro M, Coats SE, Jonkman MF, Jonkmann MF, Leigh IM, Lane EB
… Continue reading →

Posted in J Invest Dermatol | Tagged , | Comments Off on Keratin 14-null cells as a model to test the efficacy of gene therapy approaches in epithelial cells.